Boehringer’s schizophrenia asset fails Phase 3; GSK buys organoid biotech

Plus, news about Kodiak Sciences, Outlook Therapeutics and Avacta:

Boehringer Ingelheim reports Phase 3 schizophrenia fail: The drug, iclepertin,

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Bidco to acquire biopharmaceutical services company Ergomed

Ergomed is engaged in the outsourced pharma services sector. Credit: Lucas Vasques on Unsplash. Eden AcquisitionCo (Bidco) has signed an agreement to acquire British biopharmaceutical

September 4, 2023

Computational tools reveal 3D structures of viral proteins

These rapid shifts mean that researchers are still trying to understand a multitude of viral proteins and precisely how they increase viruses’ infecting abilities-; knowledge

August 27, 2024

Opinion | Mandatory Retirement Age for Physicians: Yea or Nay?

In this video, healthcare marketing consultant Ron Harman King, JD, MS, discusses the ongoing debate on whether physicians could be legally forced to retire at

September 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.